Homologous recombination deficiency (HRD). An HRD test is being applied to patient samples to identify BRCA1/BRCA2 mutated tumors, provide a categorical determination of tumor HRD, and determine an enrichment strategy for patients with tumors that are sensitive to Niraparib treatment.
Suggested Pages #
- 0.025 Pancreatic cancer
- 0.025 HR
- 0.025 February 13
- 0.025 Journal of Clinical Oncology
- 0.025 상동재조합
- 0.025 DNA repair
- 0.025
- 0.025 Ovarian cancer
- 0.013 Mutational signature
- 0.013 Breast cancer
- More suggestions...